Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2. More: Lilly’s atopic dermatitis drug hits endpoints Source: News
read moreThe committee also cited concerns about the economic models provided by the company. More: NICE to work with GW Pharma after Epidiolex rejection Source: News
read moreBelantamab mafodotin is on track for regulatory submission by the end of 2019. More: Positive multiple myeloma results for GSK Source: News
read moreThe indication, chronic kidney disease, is a serious, progressive condition defined by decreased kidney function. More: FDA Fast Track granted for AZ’ Forxiga Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals